You are here: Home: VP Audio Programs: VP BC 1 | 2008 Audio: VP BC1 | 2008

To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.

Track 1	A woman with triple-negative breast cancer who had received prior adjuvant chemotherapy. She developed symptomatic pulmonary metastases and was treated with carboplatin/ gemcitabine and bevacizumab. She had rapid improvement in symptomatology but developed dermatomyositis.
Track 2	A woman with HER2-positive metastatic breast cancer and extensive postmastectomy chest wall recurrence who received several trastuzumab-based regimens followed by lapatinib and capecitabine. Capecitabine was discontinued due to toxicity, and she has been receiving single-agent lapatinib for 14 months.
Track 3	A 42-year-old woman who presented 14 years ago with ER-positive, PR-positive, node-positive, Grade II invasive ductal cancer. She had a mastectomy and received four cycles of adjuvant AC. Five years after her diagnosis, she had her second child. In 2006, she had an elevated CA27.29, and a PET scan revealed metastatic disease that was not accessible for biopsy. She was treated with an aromatase inhibitor and goserelin.
Track 4	A woman with symptomatic, ER-positive, HER2-positive metastatic breast cancer who was treated with multiple trastuzumab-containing regimens. She had preexisting dementia and now has progressive brain metastases after radiosurgery.
Track 5	A woman with triple-negative breast cancer presented with sternal, lung and liver metastases. She was enrolled on a clinical trial and was randomly assigned to receive bevacizumab in combination with weekly paclitaxel.
Track 6	A woman who initially presented with a 7-cm, ER-positive, PR-positive, HER2-negative, poorly differentiated breast tumor with bone and liver metastases. She received exemestane and zoledronic acid. After eight months, she had disease progression in the bone. She was started on fulvestrant and underwent mastectomy. She did not respond to fulvestrant and was enrolled in a clinical trial in which she was randomly assigned to receive paclitaxel and bevacizumab.